Matthew Angel, CEO and President at Tempest Therapeutics, bought TPST on Mar 24, 2026
Data as of Oct 16
- Traded
- Mar 24, 2026
- Disclosed
- Jun 23, 2026
- Filed
- 91 days after the trade · late
Form 4s are due within two business days.
Official filing (SEC Form 4) ↗
The price around the disclosure
TPST since disclosure
−50.3%
Similar stocks (XLV) since disclosure
+16.1%
XLV — its sector index fund
Change in closing price from Jun 23, 2026 (the first trading day on or after disclosure) to Oct 16, 2026. Dividends excluded. Not a return anyone earned.
Our take
- Not enough evidence · In past tests: 6.6 percentage points better than similar stocks over 3 months · 904 tries